Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 909-044-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There no data available on phosphonic ester residue with respect to repeated dose toxicity.
Regarding the individual components of phosphonic ester residue the only available data are provided by Dimethylphosphonate(accounting for about 11 % in phosphonic acid ester residue) by oral and inhalation exposure. The NOAEL (rat ,oral, subchronic exposure) is 100 mg/kg bw/day and the LOAEL(rat, inhalation exposure, subacute) is 12ppm (48.7 mg/m³).
Key value for chemical safety assessment
Additional information
There no data available on phosphonic ester residue with respect to repeated dose toxicity.
Phosphonic ester residue contains monomethyl phosphonate, phosphonic acid, and Dimethylphosphonate, and and salt of pyrophosphoric acid. and phosphate which were not further specified
ORAL APPLICATION
Monomethylphosphonate and phosphonic acid
there are no data available
Dimethylphosphonate - oral applicationThere is a 2 -year repeated dose toxicity study in male and female F344 rats available in which only mortality, body weight development and tumour development were considered; clinical signs, biochemical or clinical chemical effects were not considered. Based on these limitations, this study was not taken into account with respect to repeated dose toxicity.
In a 13 week gavage study male and female Fischer 344 rats were administered 25, 50, 100, 200, 400 mg/kg bw/day dimethyl phosphonate on 5 days/week within the National Toxicology Program (US Health and Human Services 1985). This study was chosen as key study because it was the most critical study in terms of general toxicology despite the lack of data of hematology, clinical chemistry or urinalysis. The NOAEL was determined 100 mg/kg bw/day for female rats and 200 mg/kg bw/day for male rats based on increased mortality, decreased body weight, eye changes (degeneration of the lens, acute diffuse inflammation of the cornea), increased lung lesions (inflammation, congestion, histiocytosis) and in male rats increased urinary bladder calculi at the highest test dose.
Salt of pyrophosphoric acid and phosphate (not further specified)
There are no data available
INHALATION EXPOSURE
Monomethylphosphonate and phosphonic acid
there are no data available
DimethylphosphonateOECD-ICCA_SIDS (published by UNEP 2006) reported that in a 4-week study, male and female Sprague-Dawley rats (20/sex per group) inhaled 48.7, 142.1, 483.1, and 803.9 mg/m3 (12, 35, 119, and 198 ppm) DMP vapor for 6 hours/day on 5 days/week
(Mobil Oil Corporation, 1982).
At all concentrations increased kidney weights were observed in
male and female rats. Irritation of superficial ocular structures, mucosal irritation and keratitis were
shown in all dose groups and in both sexes. The eye changes progressed to cataracts in dose groups
of ≥ 142.1 mg/m3. At ≥ 142.1 mg/m3 cutaneous irritation was observed, the skin effects progressed
to dermatitis at 483.1 mg/m3, and at 803.9 mg/m3 necrosis and acute purulent inflammation of the
skin were main causes of deaths. At 142.1 mg/m3 inflammation of the anterior nares was visible in
male and female rats. At 483.1 mg/m3 the external nares were affected, and at 803.9 mg/m3 red
discoloration of the lungs and the nasal turbinates were observed in both sexes.
In male rats reduced body weight gains were observed at ≥ 142.1 mg/m3. In the next higher dosage
(483.1 mg/m3) body weight losses and increased mortality was shown in male and female rats.
Time to death varied between 7 and 26 days at 483.1 and 803.9 mg/m3. Hypospermatogenesis was
observed in male rats at lethal doses of ≥ 483.1 mg/m3 (details see chapter 3.1.8). Hematopoiesis in
the spleen occurred in 4/18 female rats at 803.9 mg/m3 only and was not observed in the controls or
the lower doses. No historical control data were provided.
The LOAEL derived for this study is 48.7 mg/m3 (12 ppm; corresponds to about 10 mg/kg bw/d).
No NOAEL was achieved in this study
Salt of pyrophosphoric acid and phosphate (not further specified)
There are no data available
DERMAL APPLICATION
There are no data avialble of the individual components of phosphonic ester residue
Justification for classification or non-classification
There no data available on phosphonic ester residue with respect to repeated dose toxicity
ccording to GHS/CLP Regulation 1272/2008 section 3.9.3.4.Where there is no reliable evidence or test data for the specific mixture itself then the classification of the mixture is based on the cassification of the ingredient substances.
Regarding the available test data results of the ingredient substance Dimethylphophonate, there is no classification required. Therefore no classification/labelling for phosphonic ester residue has to be required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.